The National Institute for Health and Care Excellence issued a positive Final Appraisal Determination for Cell Therapeutics Inc.’s (Nasdaq: CTIC) non-Hodgkin lymphoma treatment Pixuvri sending the stock price soaring 44 cents to $2.64.
Positive FAD For Cell Therapeutics
January 06, 2014 at 06:16 AM EST
